← All articles

Court Blocks Advisory Panel's Move to End Newborn Hepatitis B Vaccine

A federal advisory committee voted to end the hepatitis B vaccination recommendation for newborns, but a federal judge has temporarily blocked the committee's decisions. The legal challenge raises questions about the authority of the RFK Jr.-appointed panel.

AI-assisted reporting

The essentials

A judge temporarily blocked an advisory committee's vote to end newborn hepatitis B vaccine recommendations.

A federal advisory committee appointed by RFK Jr. voted to end the recommendation for hepatitis B vaccination in newborns, marking a significant shift in longstanding U.S. public health policy.

However, a federal judge has issued a temporary block on decisions made by this committee, halting the move before it could take effect. The court ruling introduces legal uncertainty over the scope of the advisory body's authority.

The outcome of this legal challenge may determine whether the hepatitis B vaccine recommendation is ultimately altered or reinstated. This policy dispute unfolds amid a broader documented trend of rising newborn vaccine refusals across the United States.

Broaden the view

Other ways to read this story.

Alternative framings generated by SigNews. These are not independent sources or attributed quotations.

Policy

Advisory Committee Vote Challenges Decades of Newborn Vaccine Policy

The committee's vote to end the hepatitis B vaccination recommendation represents a direct challenge to established U.S. public health guidance. The subsequent court block signals that institutional and legal structures may limit how quickly such advisory panels can redirect longstanding medical protocols, leaving the policy status in flux pending further judicial review.

Legal

Federal Judge Steps In as Vaccine Panel's Authority Is Disputed

The temporary judicial block on the advisory committee's decisions raises questions about the legal standing and scope of authority of RFK Jr.-appointed panels. The ruling pauses any immediate policy change, positioning the courts as a key arbiter in disputes over how federal vaccine recommendations are made and by whom.